Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | HPGD | P15428 | 8/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148621 | 0.85 | MAPT (0.66) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL29375113 | 0.82 | KDM4E (0.72) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL550572 | 0.82 | CA1 (0.57) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL192100 | 0.82 | KDM4E (0.72) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL24820015 | 0.81 | KDM4E (0.61) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL204112 | 0.81 | CA1 (0.55) | MAPTKDM4EALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL1223871 | 0.81 | KDM4E (0.70) | MAPTKDM4EALDH1A1HPGDGAA | |
| Ammonia Solution, Strong SCHEMBL5311634 | 0.81 | KDM4E (0.70) | MAPTKDM4EALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL7251305 | 0.81 | KDM4E (0.70) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL27041420 | 0.81 | CA12 (0.56) | MAPTKDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118846052-A | Medicament for targeting ASPM 963-1263 amino acid region and application thereof | 济宁医学院 | 2024-10-29 | — | — | CN | claimed |
| CN-113402440-A | 5-hydroxymethyl-2-mercaptomethyl-1-methyl-1H-indole-3-carboxylic acid ethyl ester derivative and preparation and application thereof | 山东大学 | 2021-09-17 | — | — | CN | claimed |
| CN-111892553-A | Method for synthesizing ammonium acetate mediated benzothiazole compound | 衡阳师范学院 | 2020-11-06 | — | — | CN | claimed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| US-12566113-B2 | Reversible fixing reagents and methods of use thereof | 10X GENOMICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4081777-B1 | REVERSIBLE FIXING REAGENTS AND METHODS OF USE THEREOF | 10X GENOMICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250216300-A1 | REVERSIBLE FIXING REAGENTS AND METHODS OF USE THEREOF | 10X GENOMICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4559903-A1 | PRODUCTION METHOD FOR TAFAMIDIS OR SALT THEREOF | Shiratori Pharmaceutical Co., Ltd. (JP) | 2025-05-28 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | MAPT 663/4885KDM4E 1869/4885ALDH1A1 4346/4885 |
| US-12566113-B2 | Reversible fixing reagents and methods of use thereof | SMCHD1, H1-10, FLT3 | MAPT 2837/4885KDM4E 333/4885ALDH1A1 117/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | MAPT 3420/4885KDM4E 2245/4885ALDH1A1 228/4885 |
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | MAPT 4847/4885KDM4E 3773/4885ALDH1A1 3560/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | MAPT 4663/4885KDM4E 342/4885ALDH1A1 4093/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | MAPT 1802/4885KDM4E 3715/4885ALDH1A1 385/4885 |
| US-20250216300-A1 | REVERSIBLE FIXING REAGENTS AND METHODS OF USE THEREOF | PTMS, FGB, CPSF1 | MAPT 1956/4885KDM4E 41/4885ALDH1A1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.